Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ABMD Abiomed > Key Indicators
ABMD Abiomed
381.120
+3.330+0.88%
YOY
Do not show
Hide blank lines
(Q2)2022/09/30(Q1)2022/06/30(FY)2022/03/31(Q4)2022/03/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-6.76% 145.4818 -11.87% 137.8233 -13.43% 134.9155 -13.43% 134.9155
Receivable Turnover(T)
2.19% 11.6722 7.28% 11.7534 17.88% 10.9885 17.88% 10.9885
Inventory Turnover(T)
2.30% 2.1314 10.42% 2.185 13.63% 2.1499 13.63% 2.1499
Fixed Assets Turnover(T)
5.93% 5.3043 6.12% 5.143 7.94% 4.9694 7.94% 4.9694
Total Asset Rate(T)
-2.28% 0.6658 -3.28% 0.6681 4.18% 0.6514 4.18% 0.6514
ROIC
16.71% 13.562% 13.33% 14.527% -62.21% 7.118% -62.21% 7.118%
ROE
57.00% 18.244% 19.39% 15.303% -48.83% 9.637% -48.83% 9.637%
ROA
58.42% 16.535% 20.67% 13.762% -48.20% 8.618% -48.20% 8.618%
FCF to Sales
-15.61% 20.224% -6.07% 24.875% -7.30% 24.194% -7.30% 24.194%
FCF to Net Income
-47.95% 81.429% -24.71% 120.762% 86.45% 182.870% 86.45% 182.870%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -2.96% 20.050% -- --
ROA 5 Year Average
-- -- -- -- -2.31% 17.612% -- --
Average 5 Years ROIC
-- -- -- -- -4.97% 19.493% -- --
Profitability Ratios TTM
Gross Margin
-0.70% 81.325% -0.27% 81.483% 1.07% 81.763% 1.07% 81.763%
Operating Margin
-11.68% 23.658% -13.20% 24.287% -8.14% 24.881% -8.14% 24.881%
Net Margin
62.13% 24.836% 24.76% 20.598% -50.28% 13.230% -50.28% 13.230%
EBITDA Margin
-11.23% 0.2622% -12.34% 0.2692% -7.77% 0.276% -7.77% 0.276%
R & D Expense Ratio
5.49% 15.570% 10.46% 15.730% 10.15% 15.840% 10.15% 15.840%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Total Assets to Common Equity
-0.30% 110.180% -0.57% 110.900% -0.95% 111.313% -0.95% 111.313%
Current Ratio
3.72% 7.9278 16.75% 7.533 15.43% 7.0525 15.43% 7.0525
Quick Ratio
5.13% 6.8242 22.90% 6.6454 16.18% 6.1334 16.18% 6.1334
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -18.43% 10.273% -- --
Revenue CAGR(5Y)
-- -- -- -- -12.00% 18.300% -- --
Net Income CAGR(3Y)
-- -- -- -- -173.34% -19.226% -- --
Net Income CAGR(5Y)
-- -- -- -- -50.23% 21.237% -- --
FCF 1 Year Growth
-- -- -- -- 170.04% 12.854% -- --
FCF CAGR(3Y)
-- -- -- -- -64.17% 6.237% -- --
FCF CAGR(5Y)
-- -- -- -- 5.76% 31.002% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.
CEO: Mr. Michael R. Minogue
Market: NASDAQ
Listing Date: 07/01/1987
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist